OUR PRODUCTS

Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas including ophthalmology, gastroenterology, and hematology.

SB11i

Biosimilar candidate

  • Molecule Ranibizumab
  • Reference Biologic Lucentis®ii
  • Therapeutic Area Ophthalmology
SB12

Biosimilar candidate

  • Molecule Eculizumab
  • Reference Biologic Soliris®iii
  • Therapeutic Area Hematology
SB15i

Biosimilar candidate

  • Molecule Aflibercept
  • Reference Biologic Eylea®iv
  • Therapeutic Area Ophthalmology
SB16

Biosimilar candidate

  • Molecule Denosumab
  • Reference Biologic Prolia®v
  • Therapeutic Area Osteology
SB26

Novel biologic

  • Molecule Ulinastatin-Fc
    Fusion Protein
  • Therapeutic Area Gastroenterology

*Pipeline last updated Dec 2020

  • iPhase I clinical trial was waived for SB11 and SB15
  • iiLucentis® is a registered trademark of Genentech
  • iiiSoliris® is a registered trademark of Alexion
  • ivEylea® is a registered trademark of Regeneron
  • vProlia® is a registered trademark of Amgen
SAMSUNG BIOEPIS

확인 취소
레이어 팝업 닫기